argenx Expands Cradle AI Platform for Antibody Discovery
argenx is expanding the use of Cradle's AI-driven protein engineering platform for antibody discovery. The company reports successful optimization of existing leads and generation of new antibody candidates. argenx aims to apply the platform to more programs, supporting its broader effort to develop antibody-based medicines.



